ERBB2 and prostate cancer: Oncolytic adenovirus constructed to express a PD-L1 blocking mini-antibody successfully blocked the interactions between PD-1 and PD-L1, and increased the killing effect of HER2 CAR-T cells in vitro, and co-administration of the oncolytic adenovirus with HER2 CAR-T cells into xenograft prostate cancer models prolonged survival 118.